EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Epigenetic Perspective of Immunotherapy for Cancers

Sunita Keshari, Praveen Barrodia, Anand Kamal Singh iD

Cells · 2023

DOI: 10.3390/cells12030365 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cells, 2023. Verfasst von Sunita Keshari und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA. Hauptthemen laut MEDLINE: Epigenomics, Neoplasms. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 138 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immunotherapy has brought new hope for cancer patients in recent times. However, despite the promising success of immunotherapy, there is still a need to address major challenges including heterogeneity in response among patients, the reoccurrence of the disease, and iRAEs (immune-related adverse effects). The first critical step towards solving these issues is understanding the epigenomic events that play a significant role in the regulation of specific biomolecules in the context of the immune population present in the tumor immune microenvironment (TIME) during various treatments and responses. A prominent advantage of this step is that it would enable researchers to harness the reversibility of epigenetic modifications for their druggability. Therefore, we reviewed the crucial studies in which varying epigenomic events were captured with immuno-oncology set-ups. Finally, we discuss the therapeutic possibilities of their utilization for the betterment of immunotherapy in terms of diagnosis, progression, and cure for cancer patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

EpigenomicsNeoplasmsHumansImmunotherapyMedical OncologyEpigenesis, GeneticTumor Microenvironment

Stichwörter der Autor:innen

cancerepigenetic drugsepigeneticsimmune checkpoint drugsimmunotherapy

Autor:innen und Institutionen

  • Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA.
  • Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA.

ORCID-Profile: Anand Kamal Singh

Zitieren

APA

Keshari, S., Barrodia, P., & Singh, A. K. (2023). Epigenetic Perspective of Immunotherapy for Cancers. Cells. https://doi.org/10.3390/cells12030365

Vancouver

Keshari S, Barrodia P, Singh AK. Epigenetic Perspective of Immunotherapy for Cancers. Cells. 2023. doi:10.3390/cells12030365

BibTeX
@article{Keshari2023,
  author = {Keshari, Sunita and Barrodia, Praveen and Singh, Anand Kamal},
  title = {Epigenetic Perspective of Immunotherapy for Cancers},
  journal = {Cells},
  year = {2023},
  doi = {10.3390/cells12030365}
}
Kostenlos starten →